Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel biomarkers and targets for ovarian carcinoma

A biomarker, ovarian cancer technology, applied in the field of new ovarian cancer biomarkers and targets, can solve problems such as inaccessibility

Inactive Publication Date: 2013-04-03
BRITISH COLUMBIA CANCER AGENCY BRANCH
View PDF5 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

DNA organized into heterochromatin is inaccessible to transcription machinery

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel biomarkers and targets for ovarian carcinoma
  • Novel biomarkers and targets for ovarian carcinoma
  • Novel biomarkers and targets for ovarian carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Example 1.0 - Identification of ARID1A mutations in ovarian cancer

[0106] Because CCC is genome stable 8，9 , which would be expected to have a restricted mutational profile and recurrent mutations, which would be evident by analysis of a small number of cases 24 .

[0107] The inventors used RNA-seq to decipher the transcriptomes of 17 ovarian clear cell carcinomas. Gene fusions and small intermediate deletions or insertions detected by methods described in recently published literature 25,33,34 , while SNV uses SNVmix, a recently published Bayesian mixture-based algorithm to detect 35 . The vast majority of SNVs are predicted to be rare germline variants rather than somatic mutations. Therefore, the inventors used the same approach that led to the identification of FOXL2 mutations in granulosa cell tumors 1 To identify genes that are recurrently mutated in CCC but not in unrelated cancer types. The inventors identified mutations in the ARID1A gene in six of se...

Embodiment 2

[0111] Example 2.0 - Identification of Other SWI / SNF Genes Mutated in Ovarian Cancer

[0112] In ARID1A-mutation-negative CCC, the inventors identified SNVs in other SWI / SNFs, including missense mutations in SMARCA4 (encoding BRG1) and in PBRM1 (encoding BAF180) ( Figure 5 ). Since mutations in ARID1A or other SWI / SNF-encoding genes were seen in 9 of 18 CCCs (50%), these events were important for the development of this cancer. In contrast, mutations in TP53, BRAF, PIK3CA, and PTEN were only found in one, two, two, and three CCCs, respectively. Based on data from previously published literature, the proportion of cases predicted to carry these mutations 15 .

[0113] for figure 1 , the SWI / SNF complex components in which mutations were detected are highlighted. All 15 genes encoding protein components of the SWI / SNF complex are shown on the left of the table. Arrows indicate that either BAF250a or BAF250b may be present in the complex. The PBAF SWI / SNF complex (not sh...

Embodiment 3

[0115] Example 3.0 Mutations in ARID1A are associated with loss of BAF250a expression

[0116] To elucidate that ARID1A mutations are associated with loss of expression, the inventors used a mouse monoclonal antibody (Abgent, Inc.) targeting the central region of the BAF250a protein. This antibody strongly stains all normal nuclei. Of the 18 clear cell carcinoma samples analyzed by RNA-seq in Example 1.0, eight showed loss of BAF250a expression. Of these eight cases, five had ARID1A mutations ( image 3 ). Interestingly, in the other three cases that stained negative for BAF250a by immunohistochemistry, no ARID1A mutation was detected by RNA-seq, suggesting that there may be other genetic or epigenetic mechanisms for the loss of BAF250a expression. Two cases with ARID1A mutations expressed BAF250a; one contained an in-frame deletion of a single amino acid in exon 20 (6018-6020delGCT(ΔL2007) in CCC01), while the other contained a premature termination in exon 18 SNV of the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Novel biomarkers and targets associated with ovarian cancer, particularly clear-cell carcinoma, endometrioid carcinoma, and uterine carcinoma, are disclosed. Mutations in genes encoding proteins that form part of the SWI / SNF chromatin remodelling protein complex, including ARID1A, or loss of expression of such proteins, including BAF250a, can be used to evaluate the likelihood endometriosis will progress or transform to cancer, to provide a prognosis for a patient with cancer, to assess whether conventional treatment is likely to be effective against a cancer, and / or in a synthetic lethal screen to identify novel targets and therapeutics for the treatment of cancer.

Description

[0001] References to related applications [0002] This application claims the benefit of U.S. Provisional Patent Application No. 61 / 326,859, filed April 22, 2010, and U.S. Provisional Patent Application No. 61 / 368,596, filed July 28, 2010, both titled "NOVEL MARKERS AND THERAPEUTIC TARGETS FOR CLEARCELL CARCINOMA OF THE OVARY", each of which is incorporated herein by express reference. technical field [0003] Embodiments of the invention relate to improved methods of treating, diagnosing, prognosing, and predicting response to therapy for certain types of cancer, and methods for screening and developing novel targets, biomarkers, and therapeutic agents for the treatment of certain types of cancer method. Embodiments of the present invention find particular application in methods of treating, diagnosing, prognosing, and predicting response to therapy for clear cell carcinoma of the ovary, endometrioid carcinoma, and uterine cancer, and relate to screening and development of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/48C12Q1/68C40B30/00G01N33/50G01N33/574G01N33/68
CPCG01N2800/50G01N2800/56G01N33/57442G01N33/5011C12Q2600/158C12Q1/6886G01N33/57449C12Q2600/106C12Q2600/118C12Q2600/136A61K31/713C12N15/1079G01N33/689
Inventor D.G.亨茨曼M.马拉K.威甘德M.赫斯特S.P.谢
Owner BRITISH COLUMBIA CANCER AGENCY BRANCH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com